• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis.描绘近期感染丙型肝炎病毒且正在接受抗病毒治疗的注射吸毒者:一项聚类分析。
Hepat Res Treat. 2014;2014:631481. doi: 10.1155/2014/631481. Epub 2014 Oct 1.
2
Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.比较直接作用抗病毒药物治疗在吸毒者和非吸毒者中 HCV 感染的疗效。
Medicina (Kaunas). 2022 Mar 17;58(3):436. doi: 10.3390/medicina58030436.
3
Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis.注射吸毒人群中丙型肝炎病毒检测的流行率和高危行为:系统评价和荟萃分析。
Subst Abuse Treat Prev Policy. 2020 Aug 24;15(1):64. doi: 10.1186/s13011-020-00306-1.
4
Incidence of hepatitis C among people who inject drugs in Ireland.爱尔兰注射毒品者中丙型肝炎的发病率。
Hepatol Med Policy. 2017 Jan 26;2:7. doi: 10.1186/s41124-017-0024-1. eCollection 2017.
5
HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India.注射吸毒者中的艾滋病毒、乙型肝炎和丙型肝炎:在印度德里观察到艾滋病毒和丙型肝炎病毒RNA阳性感染的高流行率。
BMC Public Health. 2015 Jul 30;15:726. doi: 10.1186/s12889-015-2003-z.
6
A descriptive study of hepatitis C in people who inject drugs.一项关于注射吸毒人群丙型肝炎的描述性研究。
Indian J Med Res. 2023 Nov 1;158(5&6):559-564. doi: 10.4103/ijmr.ijmr_2634_22. Epub 2024 Jan 24.
7
Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.在注射毒品者中整合丙型肝炎和成瘾治疗:圣帕特里尼亚诺 HCV 无和无毒品经验。
Viruses. 2024 Feb 28;16(3):375. doi: 10.3390/v16030375.
8
Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study.在三个不同社区医疗外展中心的高危人群中,现场快速 HIV/HBV/HCV 检测和 HBV 疫苗接种的可接受性:ANRS-SHS 154 CUBE 研究。
BMC Infect Dis. 2020 Nov 16;20(1):851. doi: 10.1186/s12879-020-05601-7.
9
Anti-Hepatitis C (HCV) test positivity and new HCV diagnoses among women tested in antenatal services in England between 2015-2019.2015-2019 年期间,英格兰产前服务中接受检测的女性中抗丙型肝炎病毒(HCV)检测阳性和新丙型肝炎病毒诊断情况。
Midwifery. 2023 Dec;127:103863. doi: 10.1016/j.midw.2023.103863. Epub 2023 Oct 31.
10
Pilot Outreach Program in Remedis-The Promising Step toward HCV Elimination among People Who Inject Drugs.Remedis 试点外展项目——在注射吸毒者中消除丙型肝炎的有希望的一步。
Int J Environ Res Public Health. 2022 Dec 28;20(1):501. doi: 10.3390/ijerph20010501.

引用本文的文献

1
Towards Targeted Interventions in Low- and Middle-Income Countries: Risk Profiles of People Who Inject Drugs in Haiphong (Vietnam).面向中低收入国家的靶向干预:海防(越南)注射吸毒人群的风险特征。
Biomed Res Int. 2020 Sep 10;2020:8037193. doi: 10.1155/2020/8037193. eCollection 2020.

本文引用的文献

1
Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents.在一个以社区为基础的大型市中心居民队列中,丙型肝炎病毒感染治疗的接受率持续较低。
Liver Int. 2014 Sep;34(8):1198-206. doi: 10.1111/liv.12370. Epub 2013 Nov 20.
2
Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users.美沙酮维持治疗在预防注射吸毒者丙型肝炎病毒传播中的有效性
Hepat Mon. 2013 Aug 17;13(8):e12411. doi: 10.5812/hepatmon.12411. eCollection 2013.
3
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.直接观察聚乙二醇干扰素联合自行给予利巴韦林治疗活跃期吸毒人群丙型肝炎病毒感染:一项随机对照试验。
Clin Infect Dis. 2013 Aug;57 Suppl 2:S90-6. doi: 10.1093/cid/cit327.
4
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.在阿片类物质替代环境中对注射吸毒者进行丙型肝炎病毒感染的评估和治疗:ETHOS 研究。
Clin Infect Dis. 2013 Aug;57 Suppl 2:S62-9. doi: 10.1093/cid/cit305.
5
Prevalence and temporal trends of crack injection among injection drug users in eastern central Canada.加拿大中东部地区注射吸毒者中注射吸食 Crack 的流行率和时间趋势。
Drug Alcohol Depend. 2013 Nov 1;133(1):275-8. doi: 10.1016/j.drugalcdep.2013.05.013. Epub 2013 Jun 12.
6
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.丙型肝炎病毒治疗预防注射吸毒人群:在直接作用抗病毒药物时代的治疗扩大规模建模。
Hepatology. 2013 Nov;58(5):1598-609. doi: 10.1002/hep.26431. Epub 2013 Aug 26.
7
Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.与注射吸毒者丙型肝炎病毒感染评估和治疗相关的知识和障碍。
Drug Alcohol Rev. 2012 Nov;31(7):918-24. doi: 10.1111/j.1465-3362.2012.00468.x. Epub 2012 May 21.
8
The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.处方类阿片类药物注射的流行率不断上升,以及其与街头吸毒者丙型肝炎发病率之间的关系。
Addiction. 2012 Jul;107(7):1318-27. doi: 10.1111/j.1360-0443.2012.03803.x. Epub 2012 Mar 22.
9
Barriers to hepatitis C treatment.丙型肝炎治疗的障碍。
Liver Int. 2012 Feb;32 Suppl 1(0 1):151-6. doi: 10.1111/j.1478-3231.2011.02706.x.
10
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.注射吸毒人群丙型肝炎病毒抗病毒治疗的成本效益分析。
Hepatology. 2012 Jan;55(1):49-57. doi: 10.1002/hep.24656. Epub 2011 Dec 6.

描绘近期感染丙型肝炎病毒且正在接受抗病毒治疗的注射吸毒者:一项聚类分析。

Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis.

作者信息

Bamvita Jean-Marie, Roy Elise, Zang Geng, Jutras-Aswad Didier, Artenie Andreea Adelina, Levesque Annie, Bruneau Julie

机构信息

CRCHUM (Centre de Recherche du Centre Hospitalier de l'Université de Montréal), Tour Saint-Antoine 850, Rue St-Denis, Montréal, QC, Canada H2X 0A9 ; Département de Médecine Familiale, Faculté de Médecine, Université de Montréal, Pavillon Roger-Gaudry, Bureau S-711, 2900 boul. Édouard-Montpetit, Montréal, QC, Canada H3T 1J4.

Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Campus Longueuil 1111, Rue St-Charles Ouest, Bureau 500, Longueuil, QC, Canada J4K 5G4.

出版信息

Hepat Res Treat. 2014;2014:631481. doi: 10.1155/2014/631481. Epub 2014 Oct 1.

DOI:10.1155/2014/631481
PMID:25349730
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4199115/
Abstract

Objectives. To empirically determine a categorization of people who inject drug (PWIDs) recently infected with hepatitis C virus (HCV), in order to identify profiles most likely associated with early HCV treatment uptake. Methods. The study population was composed of HIV-negative PWIDs with a documented recent HCV infection. Eligibility criteria included being 18 years old or over, and having injected drugs in the previous 6 months preceding the estimated date of HCV exposure. Participant classification was carried out using a TwoStep cluster analysis. Results. From September 2007 to December 2011, 76 participants were included in the study. 60 participants were eligible for HCV treatment. Twenty-one participants initiated HCV treatment. The cluster analysis yielded 4 classes: class 1: Lukewarm health seekers dismissing HCV treatment offer; class 2: multisubstance users willing to shake off the hell; class 3: PWIDs unlinked to health service use; class 4: health seeker PWIDs willing to reverse the fate. Conclusion. Profiles generated by our analysis suggest that prior health care utilization, a key element for treatment uptake, differs between older and younger PWIDs. Such profiles could inform the development of targeted strategies to improve health outcomes and reduce HCV infection among PWIDs.

摘要

目标。通过实证确定近期感染丙型肝炎病毒(HCV)的注射吸毒者(PWIDs)的分类,以便识别最有可能与早期接受HCV治疗相关的特征。方法。研究人群由有记录的近期HCV感染的HIV阴性PWIDs组成。纳入标准包括年龄在18岁及以上,且在估计的HCV暴露日期前6个月内有注射毒品行为。使用两步聚类分析进行参与者分类。结果。从2007年9月到2011年12月,76名参与者被纳入研究。60名参与者符合HCV治疗条件。21名参与者开始接受HCV治疗。聚类分析产生了4类:第1类:对HCV治疗提议不感兴趣的冷淡的健康寻求者;第2类:愿意摆脱困境的多种物质使用者;第3类:与医疗服务使用无关的PWIDs;第4类:愿意扭转命运的寻求健康的PWIDs。结论。我们的分析得出的特征表明,先前的医疗保健利用情况,这是接受治疗的一个关键因素,在年龄较大和较小的PWIDs之间存在差异。这些特征可为制定有针对性的策略提供信息,以改善健康结果并减少PWIDs中的HCV感染。